Imaging Hepatocellular Carcinoma With Ga-Citrate PET: First Clinical Experience
While cross-sectional imaging with computed tomography (CT) and magnetic resonance imaging is the primary method for diagnosing hepatocellular carcinoma (HCC), they provide little biological insight into this molecularly heterogeneous disease. Nuclear imaging tools that can detect molecular subsets...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-09-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.1177/1536012117723256 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832544612245307392 |
|---|---|
| author | Carina Mari Aparici MD Spencer C. Behr MD Youngho Seo PhD R. Kate Kelley MD Carlos Corvera MD Kenneth T. Gao Rahul Aggarwal MD Michael J. Evans PhD |
| author_facet | Carina Mari Aparici MD Spencer C. Behr MD Youngho Seo PhD R. Kate Kelley MD Carlos Corvera MD Kenneth T. Gao Rahul Aggarwal MD Michael J. Evans PhD |
| author_sort | Carina Mari Aparici MD |
| collection | DOAJ |
| description | While cross-sectional imaging with computed tomography (CT) and magnetic resonance imaging is the primary method for diagnosing hepatocellular carcinoma (HCC), they provide little biological insight into this molecularly heterogeneous disease. Nuclear imaging tools that can detect molecular subsets of tumors could greatly improve diagnosis and management of HCC. To this end, we conducted a patient study to determine whether HCC can be resolved using 68 Ga-citrate positron emission tomography (PET). One patient with recurrent HCC was injected with 300 MBq of 68 Ga-citrate and imaged with PET/CT 249 minutes post injection. Four (28%) of 14 hepatic lesions were avid for 68 Ga-citrate. One extrahepatic lesion was not PET avid. The average maximum standardized uptake value (SUV max ) for the lesions was 7.2 (range: 6.2-8.4), while the SUV max of the normal liver parenchyma was 4.7 and blood pool was 5.7. The avid lesions were not significantly larger than the quiescent lesions, and a prior contrast CT showed uniform enhancement among the lesions, suggesting that tumor signals are due to specific binding of the radiotracer to the transferrin receptor, rather than enhanced vascularity in the tumor microenvironment. Further studies are required in a larger patient cohort to verify the molecular basis of radiotracer uptake and the clinical utility of this tool. |
| format | Article |
| id | doaj-art-544cd7c49d74411c8bf1d8ef7246cf7f |
| institution | Kabale University |
| issn | 1536-0121 |
| language | English |
| publishDate | 2017-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Molecular Imaging |
| spelling | doaj-art-544cd7c49d74411c8bf1d8ef7246cf7f2025-02-03T10:08:00ZengSAGE PublishingMolecular Imaging1536-01212017-09-011610.1177/1536012117723256Imaging Hepatocellular Carcinoma With Ga-Citrate PET: First Clinical ExperienceCarina Mari Aparici MD0Spencer C. Behr MD1Youngho Seo PhD2R. Kate Kelley MD3Carlos Corvera MD4Kenneth T. Gao5Rahul Aggarwal MD6Michael J. Evans PhD7 Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA Department of Surgery, University of California, San Francisco, San Francisco, CA, USA Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USAWhile cross-sectional imaging with computed tomography (CT) and magnetic resonance imaging is the primary method for diagnosing hepatocellular carcinoma (HCC), they provide little biological insight into this molecularly heterogeneous disease. Nuclear imaging tools that can detect molecular subsets of tumors could greatly improve diagnosis and management of HCC. To this end, we conducted a patient study to determine whether HCC can be resolved using 68 Ga-citrate positron emission tomography (PET). One patient with recurrent HCC was injected with 300 MBq of 68 Ga-citrate and imaged with PET/CT 249 minutes post injection. Four (28%) of 14 hepatic lesions were avid for 68 Ga-citrate. One extrahepatic lesion was not PET avid. The average maximum standardized uptake value (SUV max ) for the lesions was 7.2 (range: 6.2-8.4), while the SUV max of the normal liver parenchyma was 4.7 and blood pool was 5.7. The avid lesions were not significantly larger than the quiescent lesions, and a prior contrast CT showed uniform enhancement among the lesions, suggesting that tumor signals are due to specific binding of the radiotracer to the transferrin receptor, rather than enhanced vascularity in the tumor microenvironment. Further studies are required in a larger patient cohort to verify the molecular basis of radiotracer uptake and the clinical utility of this tool.https://doi.org/10.1177/1536012117723256 |
| spellingShingle | Carina Mari Aparici MD Spencer C. Behr MD Youngho Seo PhD R. Kate Kelley MD Carlos Corvera MD Kenneth T. Gao Rahul Aggarwal MD Michael J. Evans PhD Imaging Hepatocellular Carcinoma With Ga-Citrate PET: First Clinical Experience Molecular Imaging |
| title | Imaging Hepatocellular Carcinoma With Ga-Citrate PET: First Clinical Experience |
| title_full | Imaging Hepatocellular Carcinoma With Ga-Citrate PET: First Clinical Experience |
| title_fullStr | Imaging Hepatocellular Carcinoma With Ga-Citrate PET: First Clinical Experience |
| title_full_unstemmed | Imaging Hepatocellular Carcinoma With Ga-Citrate PET: First Clinical Experience |
| title_short | Imaging Hepatocellular Carcinoma With Ga-Citrate PET: First Clinical Experience |
| title_sort | imaging hepatocellular carcinoma with ga citrate pet first clinical experience |
| url | https://doi.org/10.1177/1536012117723256 |
| work_keys_str_mv | AT carinamariaparicimd imaginghepatocellularcarcinomawithgacitratepetfirstclinicalexperience AT spencercbehrmd imaginghepatocellularcarcinomawithgacitratepetfirstclinicalexperience AT younghoseophd imaginghepatocellularcarcinomawithgacitratepetfirstclinicalexperience AT rkatekelleymd imaginghepatocellularcarcinomawithgacitratepetfirstclinicalexperience AT carloscorveramd imaginghepatocellularcarcinomawithgacitratepetfirstclinicalexperience AT kennethtgao imaginghepatocellularcarcinomawithgacitratepetfirstclinicalexperience AT rahulaggarwalmd imaginghepatocellularcarcinomawithgacitratepetfirstclinicalexperience AT michaeljevansphd imaginghepatocellularcarcinomawithgacitratepetfirstclinicalexperience |